Orion Pharmaceuticals RDI II

Promoteur – Intermédiaire Financier

Orion Oyj

Lieu

• Finlande

Description

The project covers Orion’s Research & Development activities in the period 2009 up to and including 2012. The focus of these activities is for projects that fall within Orion’s core areas of pharmaceutical expertise.

Objectifs

The project covers Orion’s Research & Development activities in the period 2009 up to and including 2012. The focus of these activities is for projects that fall within Orion’s core areas of pharmaceutical expertise.

Secteur(s)

• Industrie

Montant BEI envisagé (montant approximatif)

EUR 75 million.

Coût total (montant approximatif)

Over EUR 300 million.

Aspects environnementaux

The project involves activities that will be carried out within existing R&D facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA is therefore not required by the EIA Directive 85/337/EEC, amended by Directive 97/11/EC. The promoter’s R&D facilities comply with relevant EU and environmental legislation.

Passation des marchés

The R&D activities are mostly carried out by internal staff. The promoter carries out competitive enquiries among potential suppliers for goods and services. These procedures, which are typical for the industry, are in the best interests of the project and satisfactory to the Bank.

Statut

Signé - 22/12/2009